A Soluble Form of CTLA-4 Is Present in Paediatric Patients with Acute Lymphoblastic Leukaemia and Correlates with CD1d+ Expression

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Simone, Rita ^a,b   Tenca, Claudya ^a   Fais, Franco ^a   Luciani, Matteo ^c   de Rossi, Giulio ^c   Pesce, Giampaola ^d   Bagnasco, Marcello ^d   Saverino, Daniele ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD1D ANTIGEN; CD3 ANTIGEN; CD38 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA DR ANTIGEN; MESSENGER RNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGE DISTRIBUTION; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE DIFFERENTIATION; CHILD; CHILD HEALTH; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 GENE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; GENE EXPRESSION REGULATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CODE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; INFANT; MAJOR CLINICAL STUDY; MARKER GENE; PRESCHOOL CHILD; PROGNOSIS; PROTEIN BLOOD LEVEL;

ANTIGENS, CD1D; B-LYMPHOCYTES; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CTLA-4 ANTIGEN; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; MALE; POLYMORPHISM, GENETIC; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RNA, MESSENGER; SOLUBILITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84866666742     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044654     Document Type: Article

References (41)

1. Pui CH, Relling MV, Downing JR, (2004) Acute lymphoblastic leukemia. N Engl J Med 350: 1535-1548.
2. Caligaris-Cappio F, Greaves MF, Grossi CE, Pistoia V (2003) Lymphoproliferative disorders. In: Zucker-Franklin D, Grossi CE (eds). Atlas of Blood Cells. Function and pathology, Vol 2. Milan: Ermes 567-661.
3. Eguchi M, Eguchi-Ishimae M, Greaves M, (2003) The role of the MLL gene in infant leukemia. Int J Hematol 78: 390-401.
4. Carroll WL, Bhojwani D, Min DJ, Raetz E, Relling M, et al. (2003) Pediatric acute lymphoblastic leukemia. Hematology (Am Soc Hematol Educ Program), 102-131.
5. Brigl M, Brenner MB, (2004) CD1: antigen presentation and T cell function. Annu Rev Immunol 22: 817-890.
6. Benlagha K, Weiss A, Beavis A, Teyton L, Bendelac A, (2000) In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers. J Exp Med 191: 1895-1903.
7. Fais F, Tenca C, Cimino G, Coletti V, Zanardi S, et al. (2005) CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis. Leukemia 19: 551-556.
8. Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, et al. (1987) A new member of the immunoglobulin superfamily-CTLA-4. Nature 328: 267-270.
9. Merlo A, Tenca C, Fais F, Battini L, Ciccone E, et al. (2005) Inhibitory receptors CD85j, LAIR-1, and CD152 down-regulate immunoglobulin and cytokine production by human B lymphocytes. Clin Diagn Lab Immunol 12: 705-712.
10. Laurent S, Carrega P, Saverino D, Piccioli P, Camoriano M, et al. (2010) CTLA-4 is expressed by human monocyte-derived DCs and its ligation modulates cytokine secretion and T cell proliferation stimulating ability. Human Immunol 71: 934-941.
11. Pistillo MP, Tazzari PL, Palmisano GL, Pierri I, Bolognesi A, et al. (2003) CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. Blood 101: 202-209.
12. Contardi E, Palmisano GL, Tazzari PL, Martelli AM, Falà F, et al. (2005) CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer 117: 538-550.
13. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, et al. (1994) CTLA-4 can function as a negative regulator of T cell activation. Immunity 1: 405-413.
14. Saito T, (1998) Negative regulation of T cell activation. Curr Opin Immunol 10: 313-321.
15. Kummel MF, Allison JP, (1996) CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med183: 2533-2540.
16. Chambers CA, Kuhns MS, Egen JG, Allison JP, (2001) CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19: 565-594.
17. Masteller EL, Chuang E, Mullen AC, Reiner SL, Thompson CB, (2000) Structural analysis of CTLA-4 function in vivo. J Immunol 164: 5319-5327.
18. Chikuma S, Imboden JB, Bluestone JA, (2003) Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4. J Exp Med 197: 129-135.
19. Greenwald RJ, Oosterwegel MA, van der Woude D, Kubal A, Mandelbrot DA, et al. (2002) CTLA-4 regulates cell cycle progression during a primary immune response. Eur J Immunol 32: 366-373.
20. Levings MK, Sangregorio R, Sartirana C, Moschin AL, Battaglia M, et al. (2002) Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells. J Exp Med 196: 1335-1346.
21. Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, et al. (2000) Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 192: 303-310.
22. Oaks MK, Hallett KM, (2000) A soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol 164: 5015-5018.
23. Saverino D, Brizzolara R, Simone R, Chiappori A, Milintenda-Floriani F, et al. (2007) Soluble CTLA-4 in autoimmune thyroid diseases: Relationship with clinical status and possible role in the immune response dysregulation. Clin Immunol 123: 190-198.
24. Purohit S, Podolsky R, Collins C, Zheng W, Schatz D, et al. (2005) Lack of correlation between the levels of soluble cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and the CT-60 genotypes. J Autoimmune Dis 31: 2-8.
25. Sato S, Fujimoto M, Hasegawa M, Komura K, Yanaba K, et al. (2004) Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. Rheumatology 43: 1261-1266.
26. Wong CK, Lit LCW, Tam LS, Li EK, Lam CWK, (2005) Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus Rheumatology. 44: 989-994.
27. Wang XB, Kakoulidou M, Giscombe R, Qiu Q, Huang D, et al. (2002) Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence. J Neuroimmunol 130: 224-232.
28. Simone R, Brizzolara R, Chiappori A, Milintenda-Floriani F, Natale C, et al. (2009) A functional soluble form of CTLA-4 is present in the serum of celiac patients and correlates with mucosal injury. Int Immunol 21: 1037-1045.
29. Wong CK, Lun SWN, Ko FWS, Ip WK, Hui DSC, et al. (2005) Increased expression of plasma and cell surface co-stimulatory molecules CTLA-4, CD28 and CD86 in adult patients with allergic asthma. Clinical Exp. Immunol 141: 122-129.
30. Saverino D, Riccio AM, Rogkakou A, Bagnasco M, Bonadonna P, et al. (2009) Serum cytotoxic T lymphocyte-associated antigen 4 in Hymenoptera venom allergy and its modulation by specific immunotherapy. J Allergy Clin Immunol 123: 258-60.
31. Simone R, Saverino D, (2009) The Soluble CTLA-4 Receptor and its Emerging Role in Autoimmune Diseases. Curr Immunol Reviews 5: 54-68.
32. Hock BD, Starling GC, Patton WN, Salm N, Bond K, et al. (2004) Identification of a circulating soluble form of CD80: levels in patients with hematological malignancies. Leuk Lymphoma 45: 2111-2118.
33. Hock BD, Starling GC, Patton WN, Salm N, Bond K, et al. (2006) Circulating levels and clinical significance of soluble CD86 in myeloma patients. Br J Haematol 133: 165-172.
34. Hock BD, Patton WN, Budhia S, Mannari D, Roberts P, et al. (2002) Human plasma contains a soluble form of CD86 which is present at elevated levels in some leukaemia patients. Leukemia 16: 865-873.
35. Hock BD, McKenzie JL, Patton WN, Haring LF, Yang Y, et al. (2003) The clinical significance of soluble CD86 levels in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer 98: 1681-1688.
36. Sun T, Hu Z, Shen H, Lin D, (2009) Genetic polymorphisms in cytotoxic T-lymphocyte antigen 4 and cancer: the dialectical nature of subtle human immune dysregulation. Cancer Res 69: 6011-6014.
37. Pawlak E, Karabon L, Wlodarska-Polinska I, Jedynak A, Jonkisz A, et al. (2010) Influence of CTLA-4/CD28/ICOS gene polymorphisms on the susceptibility to cervical squamous cell carcinoma and stage of differentiation in the Polish population. Hum Immunol 71: 195-200.
38. Qi P, Ruan CP, Wang H, Zhou FG, Xu XY, et al. (2010) CTLA-4+49A>G polymorphism is associated with the risk but not with the progression of colorectal cancer in Chinese. Int J Colorectal Dis 25: 39-45.
39. Gu X, Qi P, Zhou F, Ji Q, Wang H, Dou T, et al. (2010) +49G > A polymorphism in the cytotoxic T-lymphocyte antigen-4 gene increases susceptibility to hepatitis B-related hepatocellular carcinoma in a male Chinese population. Hum Immunol 71: 83-87.
40. Hou R, Cao B, Chen Z, Li Y, Ning T, et al. (2010) Association of cytotoxic T lymphocyte-associated antigen-4 gene haplotype with the susceptibility to gastric cancer. Mol Biol Rep 37: 515-520.
41. Pérez-Garcìa A, Brunet S, Berlanga JJ, Tormo M, Nomdedeu J, et al. (2009) CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy. Leukemia 23: 486-491.